Sentences with phrase «products under development»

«We have a whole list of products under development for this year and the following years, depending on how these relationships work out,» says Pat Patterson, vice president of marketing for CRG.

A high - end device codenamed McLaren with a possible release in Q3 / Q4 is among the other new products under development.

Embedded Downloads announced the new product in a memorandum dated 31 January 2018 in which they also give an update on current products under development.

This is true whether the escrow materials include new products under development or products the customer has been purchasing for years.

We intend to retain our leadership position by remaining committed to delivering high - quality entertainment experiences to players around the world, not only with World of Warcraft but also future products under development, like StarCraft 2 and Diablo III.

Participants will provide feedback on products under development by TeachingWorks.

On a daily basis, we approve the learning design of individual products under development.

Monoclonal antibodies now account for roughly half of all new therapeutic products under development, and those already on the market generated $ 48 billion in global sales in 2010.

So far, however, such products under development often are made with toxic, expensive organic dyes.

Products under development include commercial grade flour and a flour milled from garbonzo beans.

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

* BD ™ AbSeq is a product under development, not available for sale.

«During the call, Henry said of the product under development, «I'm sitting here between two beautiful ladies.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, and capital markets conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; and (11) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10 - K for the year ended Dec. 31, 2017, and any subsequent quarterly reports on Form 10 - Q (the «Reports»).

Under Porcini, design has become an integral part of product development and marketing.

When errors or empty shelves are discovered, Bossa Nova sends a meesage to a human worker, who is summoned to do the restocking (manipulating goods is a complex mechanical task still under development, so a human worker is needed to handle products).

DALLAS, August 20, 2014 — Highland Capital Management, L.P., («Highland»), a Dallas - based investment management firm, which together with its affiliates has approximately $ 19 billion in assets under management, today announced the launch of its non-traded product line with a publicly - registered Business Development Company (BDC) NexPoint Capital, Inc..

Under the Bonus Plan, our compensation committee, in its sole discretion, determines the performance goals applicable to awards, which goals may include, without limitation: attainment of research and development milestones, sales bookings, business divestitures and acquisitions, cash flow, cash position, earnings (which may include any calculation of earnings, including but not limited to earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation and amortization and net earnings), earnings per share, net income, net profit, net sales, operating cash flow, operating expenses, operating income, operating margin, overhead or other expense reduction, product defect measures, product release timelines, productivity, profit, return on assets, return on capital, return on equity, return on investment, return on sales, revenue, revenue growth, sales results, sales growth, stock price, time to market, total stockholder return, working capital, and individual objectives such as MBOs, peer reviews, or other subjective or objective criteria.

What it does have, though, is a little more than the bully pulpit because these reforms [to financial regulations] that are under way are the product of a process where all the major economies are around the table and they're participating in their development, and then they agree ultimately at the leader level in the G20.

Examples of forward - looking statements include, but are not limited to, statements we make regarding the Company's plans, assumptions, expectations, beliefs and objectives with respect to store openings and closings; product introductions; sales; sales growth; sales trends; store traffic; retail prices; gross margin; operating margin; expenses; interest and other expenses, net; effective income tax rate; net earnings and net earnings per share; share count; inventories; capital expenditures; cash flow; liquidity; currency translation; growth opportunities; litigation outcomes and recovery related thereto; the collectability of amounts due under financing arrangements with diamond mining and exploration companies; and certain ongoing or planned product, marketing, retail, manufacturing, information systems development, upgrades and replacement, and other operational and strategic initiatives.

The poor countries (writes the Peruvian priest, Father Gustavo Gutierrez) are becoming ever more clearly aware that their under development is only the by - product of the development of other countries....

«By that point, I had worked in product development in small, medium and multi-national food companies, so I had enough under my belt to be solely responsible for the R & D department, then only myself at the time.

Other items under development include a new organic line of products as well as sustainable packaging such as plastic stand - up pouches that can serve as an alternative to tin cans.

Picard will retain its name and continue manufacturing products under that brand, Business Development Director Thomas Hinton says.

Tony Candeloro is vice president of product development and client information services for ARI, one of the largest fleet management companies in the world with nearly 1.5 million vehicles under its watch.

Under his leadership, he led a variety of new product development initiatives which have distinguished the company as a technology leader in the foodservice industry.

There are national ice cream awards held once a year and the whole R&D team traditionally devotes some extra time to the product development lab, mixing and concocting flavours which normally would not be able to be made under usual factory production constraints.

Farmers carrying out organic cotton production are supported by the Export Promotion of Organic Products from Africa (EPOPA) under the Swedish International Development Co-operation Agency (SIDA).

For example, would we first plan our menu under the old regulations, and then take the time to create new recipes or assume new product developments to figure out how they'd fit the proposed (and changing) new regulations?

With all the safety concerns regarding soft bedding items in cribs, you have to sift through a lot of changing opinions, but most of the official guidelines pertain to infants under 12 months of age (from organizations like The U.S. Consumer Product Safety Commission, the American Academy of Pediatrics, and the National Institute of Child Health and Human Development).

To further support the development of industrial hemp as an agricultural product, the legislation Governor Cuomo signed today will clarify that industrial hemp will be treated the same as other crops and seed under state law.

«In another development, NAF helicopter gunships have also destroyed 9 hidden barges with stolen oil products in several creeks within the Niger Delta under the framework of Operation Delta Safe.

Filed Under: Local News Tagged With: Chautauqua County Department of Planning and Economic Development, Chautauqua County Industrial Development Agency, Coronado Stone Products, Mel Bacon

Because the products are still under development and can not be made public, there would be no room for graduate students to be able to publish their work.

Under development by the creative think tank The Living, this new product takes a cue from animal respiratory systems.

At the meeting, GlaxoSmithKline (GSK) of Rixensart, Belgium, which has the vaccine furthest in development, spelled out how it might scale up production in parallel with the safety and efficacy trials now under way so that the product could be ready for wider distribution by April if warranted.

The prototype products and ideas developed under PANTHER are ready for the next step in their development: to be tested in real - world environments, Czuchlewski said.

Such offices shall engage in cooperative research, development, and demonstration projects with the academic community, State Climate Offices, Regional Climate Offices, and other users and stakeholders on climate products, technologies, models, and other tools to improve understanding and forecasting of regional and local climate variability and change and the effects on economic activities, natural resources, and water availability, and other effects on communities, to facilitate development of regional and local adaptation plans to respond to climate variability and change, and any other needed research identified by the Under Secretary or the Advisory Committee.

An expanded innovative line of ketogenic products is under development and will soon be available.

Presenters: Sean Slade, director of Whole Child Programs, ASCD; Lee Yee Cheong - Lim, deputy director of the Health Promotion Board under the Singapore Ministry of Health, Singapore; Louise Rowling, associate professor for health promotion in the faculty of education and social work at the University of Sydney, Australia; and Jo Mason, acting national business manager and national professional product development manager for the Principals Australia Institute and MindMatters, Australia

Additionally, under Dr. Carter's leadership, ASCD grew the association's professional development programs, products, and services, including publishing capabilities, conferences and institutes, and digital offerings.

Acura, on the other hand, suffered under a previous executive that gutted much of the brand's product development budget in the face of declining sales, canceling many vehicles and projects that would have elevated the brand's status among consumers.

Don't ask a Hyundai product rep to comment on whether the Veloster's existence could have ramifications for the development of future sport compacts under the Kia banner.

The Chrysler 300 is the first large volume vehicle completely designed and engineered under the Chrysler Development System (CDS), the comprehensive, coordinated product creation process that improves quality and speed to market while reducing costs and encouraging innovation in new products.

Street - and Track - tested Quality The all - new 2007 Dodge Caliber SRT4 was designed and engineered under the Chrysler Development System (CDS), the comprehensive, coordinated and disciplined product - creation process that improves quality and speed - to - market while reducing costs and encouraging practical innovation in new vehicles.

But Land Rover did find the guts (and opportunity) to put its product to the test against the then - under - development first - generation BMW X5 on an off - road course and proved with more than flying colours that the Range Rover would continue to be a serious luxury off - roader.

The product development team at General Motors under Mark Reuss is not afraid to take chances, and some, such as the reintroduction of the midsize Chevrolet Colorado and GMC Canyon pickups, have been...

Here is a list of aerodynamic performance products that we currently have under development: - Carbon Fiber 3pc Front Air Dam / Splitter - Carbon Fiber Side Rocker Extensions - Carbon Fiber 2pc Rear Diffuser - Carbon Fiber Rear Deck Spoiler - Carbon Fiber Side Mirrors - Carbon Fiber Hood Vent - Carbon Fiber Front Fender Vents - Carbon Fiber Rear Fender / Quarter Panel Vents